Jeevan Scientific Technology

Jeevan Scientific Technology FCF/Debt

The Free Cash Flow to Debt Ratio of Jeevan Scientific Technology (538837.BO) as of Oct 21, 2026 is -76.88 %. In the previous year, Free Cash Flow to Debt Ratio was -50.80 % — a change of 51.35% (lower).

FCF/Debt

-76.88 %

YoY

51.35%

Last updated:

Free Cash Flow to Debt Ratio of Jeevan Scientific Technology is 2026 -76.88 % . Free Cash Flow to Debt Ratio of Jeevan Scientific Technology was 2025 -50.80 % . It decreases by 51.35% lower compared to the previous year.

The Jeevan Scientific Technology FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2019
-26.04 INR
Jan 1, 2020
-13.07 INR
Jan 1, 2021
53.04 INR
Jan 1, 2022
257.26 INR
Jan 1, 2023
-485.18 INR
Jan 1, 2024
-113.51 INR
Jan 1, 2025
-50.80 INR
Jan 1, 2026
-76.88 INR
The Jeevan Scientific Technology FCF/Debt history
YEARFCF/DebtYoY
-76.88 %+51.35%
-50.80 %-55.25%
-113.51 %-76.60%
-485.18 %-288.59%
257.26 %+385.03%
53.04 %-505.68%
-13.07 %-49.80%
-26.04 %-49.48%
-51.55 %-74.41%
-201.40 %+14,393.45%
-1.39 %-93.34%
-20.87 %-659.22%
3.73 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jeevan Scientific Technology Stock analysis

What does Jeevan Scientific Technology do? Jeevan Scientific Technology Ltd generates revenue by providing global management consulting and technology services through its core segments of clinical research and information technology. The company leverages its expertise in outsourcing to support clients with a comprehensive suite of offerings, including clinical operations, bioanalytical research, and pathology laboratory services. These capabilities are structured to address specific needs within the pharmaceutical and healthcare sectors, ensuring robust support for complex scientific and regulatory requirements. The firm monetizes its clinical research services by delivering specialized solutions such as bioanalytical and bioequivalence studies, clinical trials, and trial management. Additional revenue streams are created through pharmacovigilance services, which encompass risk management plans and signal detection. The company also provides essential support functions like medical writing, clinical trial monitoring, drug safety management, and clinical data management, thereby offering end-to-end solutions for its clients. In the information technology segment, Jeevan Scientific Technology Ltd complements its scientific services with technical expertise in biostatistics, statistical programming, and quality assurance. By integrating these IT services with its clinical research capabilities, the company delivers a unified value proposition to its customer base. This integrated approach allows the firm to capture value across multiple touchpoints in the clinical development lifecycle, from initial study design to final data analysis and safety monitoring. Jeevan Scientific Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jeevan Scientific Technology stock

Free Cash Flow to Debt Ratio of Jeevan Scientific Technology is -76.88 % in 2026.

Free Cash Flow to Debt Ratio of Jeevan Scientific Technology changed from -50.80 % to -76.88 %, representing a 51.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Jeevan Scientific Technology since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Jeevan Scientific Technology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Jeevan Scientific Technology

All Key Metrics — Jeevan Scientific Technology